Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Syncytial Virus Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

NCT06143046
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
0 Years to 40 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
22
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of BLB-201 RSV Vaccine in Infants and Children

NCT05655182
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
PIV5-vectored RSV Vaccine (BLB-201) Low Dose, PIV5-vectored RSV Vaccine (BLB-201) High Dose, Placebo
Biological · Drug
Lead sponsor
Blue Lake Biotechnology Inc.
Industry
Eligibility
6 Months to 5 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
18
States / cities
La Mesa, California • Modesto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-323 in Healthy Subjects

NCT05587478
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-323, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 9, 2026, 5:40 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

NCT06102174
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Placebo, Active
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 60 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 9, 2026, 5:40 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults

NCT06843317
View directory record Official record
Conditions
RSV Infection
Interventions
Candidate vaccine, SCB-1019T, AREXVY, placebo
Biological · Other
Lead sponsor
Clover Biopharmaceuticals USA, LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Fort Myers, Florida • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

NCT02873286
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA-BN-RSV, Placebo
Biological · Other
Lead sponsor
Bavarian Nordic
Industry
Eligibility
55 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
12
States / cities
Redding, California • San Diego, California • The Villages, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 9, 2026, 5:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants

NCT00983606
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
222
States / cities
Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 196 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT01852266
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV cps2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

NCT06097299
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MEDI-557 Adult Dosing

NCT01562938
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, MEDI-557
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

NCT05281263
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
CPI-RSV-F Vaccine (BLB-201)
Biological
Lead sponsor
Blue Lake Biotechnology Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Cincinnati, Ohio • North Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 9, 2026, 5:40 AM EDT
Completed No phase listed Observational

Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants

NCT06424795
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
3 Days to 10 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

NCT04657198
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine (GSK3844766A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Lenexa, Kansas • Elkridge, Maryland • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

NCT04032093
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
145
States / cities
Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 9, 2026, 5:40 AM EDT
Completed No phase listed Observational

Idylla IFV-RSV Panel Clinical Testing

NCT02786381
View directory record Official record
Conditions
Respiratory Tract Infections, Influenza, Human, Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
Not listed
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806

NCT01801293
View directory record Official record
Conditions
RSV Infection
Interventions
GS-5806
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

NCT05687279
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
RSVt Vaccine, Control Group
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 23 Months
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Norfolk, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT02601612
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
D46cpΔM2-2 vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 60 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

NCT02878330
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
Up to 365 Days
Enrollment
1,453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
60
States / cities
Birmingham, Alabama • Anaheim, California • Downey, California + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

NCT00345670
View directory record Official record
Conditions
Healthy
Interventions
MEDI-534
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Year to 9 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
12
States / cities
Fountain Valley, California • Shawnee, Kansas • Topeka, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2008 · Synced Oct 9, 2026, 5:40 AM EDT
Withdrawn No phase listed Observational

Analysis of Lung Sounds Collected by RESP Biosensor to Support Decision Making in Monitored Hospitalized Pediatric Patients

NCT05661422
View directory record Official record
Conditions
Pediatric Respiratory Diseases, Asthma, RSV Infection, COVID-19
Interventions
RESP™ Biosensor
Device
Lead sponsor
Strados Labs, Inc.
Industry
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 9, 2026, 5:40 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Transplacental Transmission of RSV (TTRSV)

NCT05443607
View directory record Official record
Conditions
SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
2
States / cities
Metairie, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Prospective Pilot Clinical Trial of Azithromycin Treatment In Respiratory Syncytial Virus (RSV)- Induced Respiratory Failure In Children

NCT02707523
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Azithromycin 10 mg, Azithromycin 20mg, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 9, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers

NCT01489306
View directory record Official record
Conditions
Drug Safety
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 9, 2026, 5:40 AM EDT